FINAZZI, MARIA CHIARA
FINAZZI, MARIA CHIARA
Dipartimento di Oncologia ed Emato-Oncologia
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
2020 A. Carobbio, P. Guglielmelli, E. Rumi, C. Cavalloni, V. De Stefano, S. Betti, A. Rambaldi, M.C. Finazzi, J. Thiele, A.M. Vannucchi, A. Tefferi, T. Barbui
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy
2014 J. Golay, A. D'Amico, G. Borleri, M. Bonzi, R. Valgardsdottir, R. Alzani, S. Cribioli, C. Albanese, E. Pesenti, M.C. Finazzi, G. Quaresmini, D. Nagorsen, M. Introna, A. Rambaldi
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
2013 G. Finazzi, A.M. Vannucchi, V. Martinelli, M. Ruggeri, F. Nobile, G. Specchia, E.M. Pogliani, O.M. Olimpieri, G. Fioritoni, C. Musolino, D. Cilloni, P. Sivera, G. Barosi, M.C. Finazzi, S.D. Tollo, T. Demuth, T. Barbui, A. Rambaldi
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
2010 A. Rambaldi, C.M. Dellacasa, G. Finazzi, A. Carobbio, M.L. Ferrari, P. Guglielmelli, E. Gattoni, S. Salmoiraghi, M.C. Finazzi, S. Di Tollo, C. D'Urzo, A.M. Vannucchi, G. Barosi, T. Barbui
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
2022 M. Maffioli, B. Mora, S. Ball, A. Iurlo, E.M. Elli, M.C. Finazzi, N. Polverelli, E. Rumi, M. Caramella, M.C. Carraro, M. D'Adda, A. Molteni, C. Sissa, F. Lunghi, A. Vismara, M. Ubezio, A. Guidetti, S. Caberlon, M. Anghilieri, R.S. Komrokji, D. Cattaneo, M.G. Della Porta, T. Giorgino, L. Bertù, M. Brociner, A.T. Kuykendall, F. Passamonti
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
2019 J. Mascarenhas, H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M.R. Baer, E. Ritchie, R.T. Silver, C. Kessler, E. Winton, M.C. Finazzi, A. Rambaldi, A.M. Vannucchi, D. Leibowitz, D. Rondelli, M.O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. Hexner, M. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, M.E. Salama, R.S. Weinberg, R. Rampal, J.D. Goldberg, R. Mesa, A.C. Dueck, R. Hoffman
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera : a propensity-matched study
2017 T. Barbui, A.M. Vannucchi, G. Finazzi, M.C. Finazzi, A. Masciulli, A. Carobbio, A. Ghirardi, G. Tognoni
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia : a report from the MPN subcommittee of the chronic malignancies working party of the European group for blood and marrow transplantation
2014 F. Lussana, A. Rambaldi, M.C. Finazzi, A. van Biezen, M. Scholten, E. Oldani, A. Carobbio, S. Iacobelli, J. Finke, A. Nagler, L. Volin, T. Lamy, R. Arnold, M. Mohty, M. Michallet, T. de Witte, E. Olavarria, N. Kröger
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
2018 V. De Stefano, A. Carobbio, V. Di Lazzaro, P. Guglielmelli, A. Iurlo, M.C. Finazzi, E. Rumi, F. Cervantes, E.M. Elli, M.L. Randi, M. Griesshammer, F. Palandri, M. Bonifacio, J.-. Hernandez-Boluda, R. Cacciola, P. Miroslava, G. Carli, E. Beggiato, M.H. Ellis, C. Musolino, G. Gaidano, D. Rapezzi, A. Tieghi, F. Lunghi, G.G. Loscocco, D. Cattaneo, A. Cortelezzi, S. Betti, E. Rossi, G. Finazzi, B. Censori, M. Cazzola, M. Bellini, E. Arellano-Rodrigo, I. Bertozzi, P. Sadjadian, N. Vianelli, L. Scaffidi, M. Gomez, E. Cacciola, A.M. Vannucchi, T. Barbui
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
2018 A. Tefferi, M. Mudireddy, F. Mannelli, K.H. Begna, M.M. Patnaik, C.A. Hanson, R.P. Ketterling, N. Gangat, M. Yogarajah, V. De Stefano, F. Passamonti, V. Rosti, M.C. Finazzi, A. Rambaldi, A. Bosi, P. Guglielmelli, A. Pardanani, A.M. Vannucchi
Busulfan or thiotepa based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group
2019 F. Patriarca, A. Masciulli, A. Bacigalupo, S. Bregante, C. Pavoni, M.C. Finazzi, A. Bosi, D. Russo, F. Narni, G. Messina, E.P. Alessandrino, A.M. Carella, G. Milone, B. Bruno, S. Mammoliti, B. Bruno, R. Fanin, F. Bonifazi, A. Rambaldi
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
2015 M.C. Finazzi, A. Carobbio, F. Cervantes, I.M. Isola, A.M. Vannucchi, P. Guglielmelli, A. Rambaldi, G. Finazzi, G. Barosi, T. Barbui
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms : an European Leukemia Net study
2014 I. Martinelli, V. De Stefano, A. Carobbio, M.L. Randi, C. Santarossa, A. Rambaldi, M.C. Finazzi, F. Cervantes, E. Arellano Rodrigo, S. Rupoli, L. Canafoglia, A. Tieghi, L. Facchini, S. Betti, A.M. Vannucchi, L. Pieri, R. Cacciola, E. Cacciola, A. Cortelezzi, A. Iurlo, E.M. Pogliani, E.M. Elli, A. Spadea, T. Barbui
Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival
2020 M.C. Finazzi, C. Boschini, C. Craddock, A. Rambaldi, J. Ward, R.K. Malladi
Detection of driver and subclonal mutations in myelofibrosis : clinical impact on pharmacologic and transplant based treatment strategies
2017 M.C. Finazzi, F. Lussana, S. Salmoiraghi, O. Spinelli, A. Rambaldi
Front-line therapy in polycythemia vera and essential thrombocythemia
2012 T. Barbui, M.C. Finazzi, G. Finazzi
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists
2016 V. De Stefano, M. Ruggeri, F. Cervantes, A. Alvarez-Larran, A. Iurlo, M.L. Randi, E. Elli, M.C. Finazzi, G. Finazzi, E. Zetterberg, N. Vianelli, G. Gaidano, E. Rossi, S. Betti, I. Nichele, D. Cattaneo, M. Palova, M.H. Ellis, R. Cacciola, A. Tieghi, J.C. Hernandez-Boluda, E. Pungolino, G. Specchia, D. Rapezzi, A. Forcina, C. Musolino, A. Carobbio, M. Griesshammer, E. Sant'Antonio, A.M. Vannucchi, T. Barbui
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
2012 E. Antonioli, P. Guglielmelli, L. Pieri, M. Finazzi, E. Rumi, V. Martinelli, N. Vianelli, M. Luigia Randi, I. Bertozzi, V. De Stefano, T. Za, E. Rossi, M. Ruggeri, E. Elli, R. Cacciola, E. Cacciola, E. Pogliani, F. Rodeghiero, M. Baccarani, F. Passamonti, G. Finazzi, A. Rambaldi, A. Bosi, M. Cazzola, T. Barbui, A.M. Vannucchi
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study
2022 P. Guglielmelli, A. Ghirardi, A. Carobbio, A. Masciulli, C. Maccari, B. Mora, E. Rumi, A. Triguero, M.C. Finazzi, H. Pettersson, C. Paoli, F. Mannelli, D. Vanni, A. Rambaldi, F. Passamonti, A. Alvarez-Larran, B. Andreasson, A.M. Vannucchi, T. Barbui
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
2019 A. Yacoub, J. Mascarenhas, H. Kosiorek, J.T. Prchal, D. Berenzon, M.R. Baer, E. Ritchie, R.T. Silver, C. Kessler, E. Winton, M.C. Finazzi, A. Rambaldi, A.M. Vannucchi, D. Leibowitz, D. Rondelli, M.O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. Hexner, M. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, E. Papaemmanuil, M. Salama, R. Singer-Weinberg, R. Rampal, J.D. Goldberg, T. Barbui, R. Mesa, A.C. Dueck, R. Hoffman